Home › Funds › Tetragon Partners GP Ltd › SLN

Tetragon Partners GP Ltd position in SLN

SILENCE THERAPEUTICS PLC · Health Care

Tetragon Partners GP Ltd reported holding 300,000 shares of SLN (SILENCE THERAPEUTICS PLC) in its Q2 2026 13F filing — a position valued at US$3.3M, representing 0.54% of its reported portfolio and ranking #27 among its reported holdings. Tetragon Partners GP Ltd has disclosed SLN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)300.00K sh
Reported value held$3.29M
Portfolio Weight0.54%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tetragon Partners GP Ltd's SLN position evolved

Tetragon Partners GP Ltd first disclosed a stake in SLN in Q4 2025 at 365,369 shares (US$2.2M). The position peaked in Q1 2026 at 630,161 shares, worth US$3.3M. Across 3 filings, Tetragon Partners GP Ltd increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 300,000 shares valued at US$3.3M — a reduction of -330,161 shares quarter over quarter.. Notable position changes include a 72% increase in Q1 2026 (shares rose 108% over the following quarter), a 52% trim in Q2 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 365.37K $2.22M New
Q1 2026 630.16K $3.32M Add
Q2 2026 300.00K $3.29M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SLN and 13F data

SLN (SILENCE THERAPEUTICS PLC) is a Health Care company. 35 other funds we track also report a position in SLN — the largest reported positions include Siren, L.L.C. (US$36.4M), TCG Crossover Management, LLC (US$33.3M), Redmile Group, LLC (US$23.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SLN

All SLN fund holders →

FAQ

How long has Tetragon Partners GP Ltd held SLN?

Tetragon Partners GP Ltd has disclosed SLN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Tetragon Partners GP Ltd's current position in SLN?

As of Q2 2026, Tetragon Partners GP Ltd holds 300.00K shares of SLN (SILENCE THERAPEUTICS PLC), valued at $3.29M, representing 0.54% of its reported portfolio and ranking #27.

Has Tetragon Partners GP Ltd been buying or selling SLN?

In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd reduced its position in SLN. The position peaked in Q1 2026 at 630.16K shares.

Which other funds hold SLN?

Other major institutional holders of SLN include Siren, L.L.C., TCG Crossover Management, LLC, Redmile Group, LLC, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.